A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration

Trial Profile

A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Pegpleranib (Primary) ; Ranibizumab
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 12 Dec 2016 Results of a pooled analysis from OPH1002 and OPH1003 trials published in an OphthoTech Corporation Media Release
    • 12 Dec 2016 According to a Novartis media release, data from this and another (OPH1003) studies, including secondary and exploratory efficacy endpoints, will be presented at a future medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top